Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $3.18 in the last session, up 13.17% from day before closing price of $2.81. In other words, the price has increased by $13.17 from its previous closing price. On the day, 2.09 million shares were traded.
Ratios:
We take a closer look at AQST’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 4.87.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17.
On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Jung Cassie sold 44 shares for $4.87 per share. The transaction valued at 214 led to the insider holds 0 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.82.
Stock Price History:
Over the past 52 weeks, AQST has reached a high of $5.80, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 17.20%, while the 200-Day Moving Average is calculated to be -14.23%.
Shares Statistics:
A total of 99.32M shares are outstanding, with a floating share count of 91.68M. Insiders hold about 7.70% of the company’s shares, while institutions hold 42.70% stake in the company.
Earnings Estimates
The current rating of Aquestive Therapeutics Inc (AQST) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.64 and -$0.77 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.49, with 2.0 analysts recommending between -$0.42 and -$0.55.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $11.32M. It ranges from a high estimate of $12.4M to a low estimate of $10.04M. As of the current estimate, Aquestive Therapeutics Inc’s year-ago sales were $20.1MFor the next quarter, 9 analysts are estimating revenue of $12.2M. There is a high estimate of $12.9M for the next quarter, whereas the lowest estimate is $10.89M.
A total of 9 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $47.7M, while the lowest revenue estimate was $40.49M, resulting in an average revenue estimate of $45.16M. In the same quarter a year ago, actual revenue was $57.56MBased on 8 analysts’ estimates, the company’s revenue will be $65.56M in the next fiscal year. The high estimate is $83.3M and the low estimate is $39.97M.
